Dicamba use and cancer incidence in the agricultural health study: an updated analysis
| العنوان: | Dicamba use and cancer incidence in the agricultural health study: an updated analysis |
|---|---|
| المؤلفون: | Catherine C. Lerro, Stella Koutros, Gabriella Andreotti, Dale P. Sandler, Jay H. Lubin, Aaron Blair, Christine G. Parks, Paul S. Albert, Jonathan N. Hofmann, Laura E. Beane Freeman |
| المصدر: | Int J Epidemiol |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Epidemiology, Colorectal cancer, 03 medical and health sciences, chemistry.chemical_compound, symbols.namesake, 0302 clinical medicine, Neoplasms, Occupational Exposure, Internal medicine, Dicamba, North Carolina, Humans, Medicine, Prospective Studies, 030212 general & internal medicine, Poisson regression, Pesticides, Lung cancer, Prospective cohort study, business.industry, Incidence, Cancer, General Medicine, medicine.disease, Iowa, Agricultural Workers' Diseases, Miscellaneous, chemistry, 030220 oncology & carcinogenesis, Relative risk, symbols, business, Liver cancer |
| الوصف: | Background The herbicide dicamba has been commonly used agriculturally and residentially. Recent approval of genetically engineered dicamba-resistant crops is expected to lead to increased dicamba use, and there has been growing interest in potential human health effects. A prior analysis in the Agricultural Health Study (AHS) suggested associations between dicamba and colon and lung cancer. We re-evaluated dicamba use in the AHS, including an additional 12 years and 2702 exposed cancers. Methods The AHS is a prospective cohort of pesticide applicators in Iowa and North Carolina. At enrollment (1993–1997) and follow-up (1999–2005), participants reported dicamba use. Exposure was characterized by cumulative intensity-weighted lifetime days, including exposure lags of up to 20 years. We estimated relative risks (RR) and 95% confidence intervals (CI) using multivariable Poisson regression for incident cancers diagnosed from enrollment through 2014/2015. Results Among 49 922 applicators, 26 412 (52.9%) used dicamba. Compared with applicators reporting no dicamba use, those in the highest quartile of exposure had elevated risk of liver and intrahepatic bile duct cancer (nexposed = 28, RRQ4 = 1.80, CI: 1.26–2.56, Ptrend < 0.001) and chronic lymphocytic leukaemia (CLL, nexposed = 93, RRQ4 = 1.20, CI: 0.96–1.50, Ptrend = 0.01) and decreased risk of myeloid leukaemia (nexposed = 55, RRQ4 = 0.73, CI: 0.51–1.03, Ptrend = 0.01). The associations for liver cancer and myeloid leukaemia remained after lagging exposure of up to 20 years. Conclusions With additional follow-up and exposure information, associations with lung and colon cancer were no longer apparent. In this first evaluation of liver and intrahepatic bile duct cancer, there was an association with increasing use of dicamba that persisted across lags of up to 20 years. |
| تدمد: | 1464-3685 0300-5771 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627d92927d25b95e1ace69f4d1eef7cfTest https://doi.org/10.1093/ije/dyaa066Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....627d92927d25b95e1ace69f4d1eef7cf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14643685 03005771 |
|---|